- PainChek (PCK) receives funding for a 12-month pilot program in care environments across Wales
- The developer of a smart phone-based pain assessment and monitoring app received the funding from the Gwent Regional Partnership board in Wales
- As part of phase one, the initial deployment will include 1000 beds in the residential aged care sector, before phase two sees the deployment expanded to hospices, hospitals, and palliative care facilities
- Care homes providing dementia, palliative, and learning disabilities care can apply to take part in the program, with the aim being to gather an evaluation of the use and impacts of the app-based medical device
- PainChek is up 7.14 per cent, trading at three cents at 12:01 pm AEST
PainChek (PCK) has received funding for a 12-month pilot program in care environments across Wales.
PainChek, which has developed a smart phone-based pain assessment and monitoring app, received the funding from the Gwent Regional Partnership board in Wales.
The app uses artificial intelligence and facial recognition to detect pain in those who cannot self-report, giving a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments.
As part of phase one, the initial deployment will include 1000 beds in the residential aged care sector, before phase two sees the deployment expanded to hospices, hospitals, and palliative care facilities. Each of these phases is anticipated to have a duration of six months.
PainChek said the agreement to fund the pilot is excellent news for the local and regional care sector, as well as recognition of the significant role that PainChek can play in achieving effective management of pain in numerous care and nursing settings.
Care homes providing dementia, palliative, and learning disabilities care can apply to take part in the program, with the aim being to gather an evaluation of the use and impacts of the app-based medical device.
“From our discussions with care homes, it is abundantly clear they place pain management as a high priority, however, the tools currently used are sub-optimal,” PainChek senior business development manager Tandeep Gill said.
“Using PainChek in a range of residential and nursing care homes across Gwent means we will be able to support them in improving management of pain for their residents.
This will deliver immediate benefits including an increase in the number and accuracy of assessments conducted at the point of care,” Mr Gill said.
The company said this could lead to better decision making from MDTs to reduce the prescribing of anti-psychotic medication, support one-to-one care requirements and hospital admissions, and inform improvements to dietary and nutritional strategies.
To date, PainChek has been contracted for approximately 126,000 beds across 1500 facilities globally and has performed a cumulative total of 1.3 million pain assessments.
PainChek was up 7.14 per cent, trading at three cents at 12:01 pm AEST.